Westmead Hospital is a major tertiary hospital in Sydney, Australia. Opened on 10 November 1978, the 975-bed hospital forms part of the Western Sydney Local Health District, and is a teaching hospital of Sydney Medical School at the University of Sydney.

There are 958 beds in Westmead Hospital-Department of Gynaecological Oncology ( Site 0201).

During the past decade, Westmead Hospital-Department of Gynaecological Oncology ( Site 0201) conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)" #1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "Gynecologic Oncology Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)" are "Carcinoma, Ovarian Epithelial" (1 trials), "Endometrial Neoplasms" (1 trials), "Fallopian Tube Neoplasms" (1 trials) and "Ovarian Cancer" (1 trials). Many other conditions were trialed in "Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)" in a lesser frequency.

Most popular intervention types in "Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)" are "Biological" (2 trials), "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (1 trials), "Docetaxel" (1 trials), "Paclitaxel" (1 trials), "Pembrolizumab" (1 trials) and "Placebo for pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)" are 2 trials for "Female" genders.

Currently, there are NaN active trials in "Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Westmead Hospital-Department of Gynaecological Oncology ( Site 0201), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Westmead Hospital-Department of Gynaecological Oncology ( Site 0201), 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".